Chemoinformaics analysis of 2,3-Dihydroxy-2,4-cyclopentadien-1-one
Molecular Weight | 112.084 | nRot | 0 |
Heavy Atom Molecular Weight | 108.052 | nRig | 8 |
Exact Molecular Weight | 112.016 | nRing | 1 |
Solubility: LogS | -1.21 | nHRing | 0 |
Solubility: LogP | -0.298 | No. of Aliphatic Rings | 1 |
Acid Count | 0 | No. of Aromatic Rings | 0 |
Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
Atoms Count | 12 | No. of Aliphatic Hetero Cycles | 0 |
No. of Heavy Atom | 8 | No. of Aromatic Carbocycles | 0 |
nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
nBridge Head | 0 | No. Saturated Carbocycles | 0 |
No. of Hydrogen atom | 4 | No. of Saturated Hetero Cycles | 0 |
No. of Carbon atom | 5 | No. of Saturated Rings | 0 |
No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
nHA | 3 | APOL | 13.4232 |
nHD | 2 | BPOL | 4.88083 |
QED | 0.396 |
Synth | 2.558 |
Natural Product Likeliness | 0.763 |
NR-PPAR-gamma | 0.015 |
Lipinski | Accepted |
Pfizer | Accepted |
GSK | Accepted |
Golden Triangle | Rejected |
Pgp-inh | 0.158 |
Pgp-sub | 0 |
HIA | 0.041 |
CACO-2 | -4.505 |
MDCK | 0.0000417 |
BBB | 0.71 |
PPB | 0.567599 |
VDSS | 0.325 |
FU | 0.545062 |
CYP1A2-inh | 0.179 |
CYP1A2-sub | 0.337 |
CYP2c19-inh | 0.05 |
CYP2c19-sub | 0.098 |
CYP2c9-inh | 0.01 |
CYP2c9-sub | 0.393 |
CYP2d6-inh | 0.003 |
CYP2d6-sub | 0.2 |
CYP3a4-inh | 0.005 |
CYP3a4-sub | 0.219 |
CL | 6.738 |
T12 | 0.582 |
hERG | 0.021 |
Ames | 0.918 |
ROA | 0.192 |
SkinSen | 0.858 |
Carcinogencity | 0.214 |
EI | 0.992 |
Respiratory | 0.443 |
NR-Aromatase | 0.056 |
Antiviral | No |
Prediction | 0.950261 |